Small cell lung cancer extensive stage – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:29 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Small cell lung cancer extensive stage – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Phase I/II study of DJI136 with drug combination in adult patients with extensive-stage small cell lung cancer https://clinicaltrials.eu/trial/phase-i-ii-study-of-dji136-with-drug-combination-in-adult-patients-with-extensive-stage-small-cell-lung-cancer/ Fri, 29 May 2026 04:02:49 +0000 https://clinicaltrials.eu/trial/phase-i-ii-study-of-dji136-with-drug-combination-in-adult-patients-with-extensive-stage-small-cell-lung-cancer/ The study focuses on adults who have Extensive-stage small cell lung cancer, a fast‑growing type of lung cancer that has spread beyond the original site. Participants receive an investigational therapy called DJI136, which is a CAR-T treatment—a type of therapy that modifies a person’s own immune cells to recognize and attack cancer. The treatment is given together with standard chemotherapy drugs including bendamustine hydrochloride, cyclophosphamide, fludarabine phosphate, and the antibody tocilizumab. The purpose of the trial is to learn how safe the therapy is, how well it is tolerated, and what dose may be appropriate for future research.

During the trial, participants receive the infusion of the study drugs in a medical setting and are then monitored for side effects, changes in lab tests, vital signs, and heart rhythm measured by an ECG. Researchers also look for signs that the cancer is responding, using a set of rules called RECIST to measure tumor size on scans. Outcomes such as the proportion of patients whose tumors shrink (ORR), the proportion whose disease stops growing (DCR), how long any shrinkage lasts (DoR), and the time before the cancer gets worse (PFS) are recorded. In addition, a laboratory technique known as qPCR is used to track the engineered cells in the blood. The study follows participants for several months after treatment to gather this information.

]]> Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients https://clinicaltrials.eu/trial/study-of-lutetium-177lu-oxodotreotide-and-a-drug-combination-for-patients-with-newly-diagnosed-extensive-stage-small-cell-lung-cancer/ Thu, 07 May 2026 05:47:14 +0000 https://clinicaltrials.eu/trial/study-of-lutetium-177lu-oxodotreotide-and-a-drug-combination-for-patients-with-newly-diagnosed-extensive-stage-small-cell-lung-cancer/ This clinical trial is studying extensive stage small cell lung cancer, a fast-growing type of lung cancer that has already spread widely in the body. The study is testing Lutathera (lutetium (177Lu) oxodotreotide) given together with carboplatin, etoposide, and atezolizumab during the first part of treatment, and then with atezolizumab alone during the later treatment phase. The purpose of the study is to find the best dose of Lutathera and to see whether adding it may help people live longer. In the first part of the study, people receive the treatment combination and the dose is adjusted to find a suitable amount. In the second part, one group receives Lutathera with the standard treatment, while another group receives the standard treatment without Lutathera. Treatment is given over several visits, with follow-up after treatment to see how the disease and treatment effects change over time.

Some people in the study may also receive NETSPOT (dotatate) for a special body scan, and LysaKare (arginine hydrochloride, lysine hydrochloride) may be given to help protect the kidneys during treatment with Lutathera. The study also includes checks for side effects and general safety, and treatment may be stopped or changed if the medicine is not tolerated. This trial is focused on newly diagnosed extensive stage small cell lung cancer and uses a combination of cancer medicine, immune treatment, and a targeted radioactive medicine.

]]> A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-tarlatamab-in-patients-with-extensive-stage-small-cell-lung-cancer-who-have-received-prior-treatment-and-have-a-limited-health-status/ Wed, 29 Apr 2026 15:09:52 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-tarlatamab-in-patients-with-extensive-stage-small-cell-lung-cancer-who-have-received-prior-treatment-and-have-a-limited-health-status/ This study focuses on individuals diagnosed with extensive-stage small cell lung cancer, which is a type of lung cancer that has spread to other parts of the body. The research specifically looks at patients whose cancer has continued to grow even after receiving previous treatments, such as platinum-etoposide chemotherapy combined with an immune-checkpoint inhibitor. Additionally, the study involves participants with an ECOG performance status of 2, a scale used by doctors to describe how much a person’s disease affects their daily activities and physical strength.

The purpose of this study is to evaluate the effectiveness of a drug called tarlatamab. This medication is an intravenous infusion, meaning it is delivered directly into a vein through a liquid solution. Participants in the trial will receive this treatment to see how it influences how long patients live and how the cancer responds to the medicine.

]]> A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer https://clinicaltrials.eu/trial/a-study-of-pf-08634404-and-a-drug-combination-for-adults-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:09:51 +0000 https://clinicaltrials.eu/trial/a-study-of-pf-08634404-and-a-drug-combination-for-adults-with-extensive-stage-small-cell-lung-cancer/ This study focuses on individuals with Extensive-Stage Small Cell Lung Cancer, a type of lung cancer that has spread to other parts of the body. The purpose of the study is to evaluate how well a new experimental medicine, PF-08634404, works when used together with chemotherapy, which is a type of treatment that uses powerful drugs to kill cancer cells. In this study, the experimental combination includes PF-08634404 along with etoposide and carboplatin. These medications are administered through intravenous infusion, meaning they are delivered directly into a vein.

Participants in the study may receive different treatment paths. One group will receive the combination of PF-08634404 and chemotherapy. Another group will receive a comparison treatment consisting of atezolizumab and chemotherapy. This comparison is used to see if the new experimental combination is more effective at helping people live longer, which is referred to as overall survival. The study will monitor how the body responds to the treatments and track any side effects that may occur during the course of the medical care.

]]> Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer https://clinicaltrials.eu/trial/study-of-tarlatamab-and-durvalumab-compared-to-durvalumab-alone-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:09:32 +0000 https://clinicaltrials.eu/trial/study-of-tarlatamab-and-durvalumab-compared-to-durvalumab-alone-for-patients-with-extensive-stage-small-cell-lung-cancer/ This study focuses on treating Extensive stage small cell lung cancer, a type of lung cancer that has spread to other parts of the body. The purpose of the study is to compare the effectiveness of using tarlatamab combined with durvalumab against using durvalumab alone. Participants may also receive other medications used for support, such as carboplatin, cisplatin, etoposide, dexamethasone, mannitol, argipressin, mycophenolate mofetil, infliximab, siltuximab, tocilizumab, paracetamol, or prednisolone.

The study is designed to see which treatment approach helps patients live longer, which is referred to as overall survival. Other factors being looked at include progression-free survival, which is the length of time during and after treatment that a disease does not get worse, and the time it takes for a disease to begin growing again. The study also monitors how the body responds to the medicine and any changes in symptoms like cough, chest pain, or dyspnea, which is the medical term for shortness of breath.

During the trial, participants are assigned to different groups to receive either the combination of medicines or a single medicine. Researchers will track how the drugs affect the body and any adverse events, which are unexpected or unpleasant side effects that occur during treatment. The study will also examine the amount of medicine present in the blood and how the body’s health and quality of life change over time.

]]> Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer https://clinicaltrials.eu/trial/study-of-bnt327-with-etoposide-and-carboplatin-compared-to-atezolizumab-with-etoposide-and-carboplatin-for-patients-with-untreated-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:08:40 +0000 https://clinicaltrials.eu/trial/study-of-bnt327-with-etoposide-and-carboplatin-compared-to-atezolizumab-with-etoposide-and-carboplatin-for-patients-with-untreated-extensive-stage-small-cell-lung-cancer/ This clinical trial is studying extensive-stage small-cell lung cancer in people who have not yet received treatment for their disease. Small-cell lung cancer is a type of lung cancer that grows and spreads quickly, and extensive-stage means the cancer has spread beyond one lung and nearby lymph nodes. The study will compare two different treatment approaches. One group will receive an investigational medicine called BNT327 combined with chemotherapy drugs etoposide and carboplatin. The other group will receive atezolizumab, which is an already approved medicine, combined with the same chemotherapy drugs etoposide and carboplatin. All medications in this study are given through an infusion into a vein. Some participants may also receive cisplatin as an alternative chemotherapy drug instead of carboplatin during the treatment period.

The purpose of this study is to compare how well BNT327 works compared to atezolizumab when each is given with chemotherapy, specifically by looking at how long participants live after starting treatment. The study will also examine how long participants live without their cancer getting worse, how many participants see their tumors shrink or disappear, and how long these responses last. Additionally, the study will monitor side effects and how the treatments affect quality of life and cancer-related symptoms such as coughing and shortness of breath.

This is a randomized study, which means participants will be assigned by chance to receive either BNT327 with chemotherapy or atezolizumab with chemotherapy. The study is double-blinded, meaning neither the participants nor their doctors will know which treatment group they are in during the study. Participants will receive treatment for up to 48 weeks or longer depending on how they respond to the treatment. Throughout the study, participants will have regular visits where their health, tumor size, and any side effects will be monitored through physical examinations, blood tests, imaging scans, and questionnaires about their well-being and symptoms.

]]> Testing Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition https://clinicaltrials.eu/trial/testing-tarlatamab-in-patients-with-advanced-small-cell-lung-cancer-who-have-poor-physical-condition/ Wed, 29 Apr 2026 15:07:45 +0000 https://clinicaltrials.eu/trial/testing-tarlatamab-in-patients-with-advanced-small-cell-lung-cancer-who-have-poor-physical-condition/ This study involves patients with small-cell lung cancer that has spread to other parts of the body, which is called extensive stage disease. The study is specifically for patients who have a poor performance status, meaning they have significant limitations in their daily activities due to their illness. The treatment being tested is Tarlatamab, also known by its code name AMG 757, which is given as an infusion into a vein. This medication is a powder that is mixed with liquid before being given through an intravenous infusion. Patients enrolled in this study must have already received at least one previous treatment for their cancer that included platinum chemotherapy, etoposide, and an antibody treatment called a PD-L1 antibody.

The purpose of this study is to evaluate how well Tarlatamab works in treating patients with extensive stage small-cell lung cancer who have poor performance status and to see if this treatment is practical and manageable for these patients. The study will look at how many patients are alive after twelve months of treatment, which is the main focus of the research. It will also examine how long patients live overall, how long they live without their cancer getting worse, how many patients experience shrinkage of their tumors, and how many patients can tolerate the treatment until their first disease check-up.

During the study, patients will receive Tarlatamab treatment over a period of up to twelve months. The doctors will monitor how well the treatment works by checking if tumors shrink or disappear, including tumors that may have spread to the brain. They will also carefully watch for any side effects and assess the safety of the treatment. Additionally, the study will measure how the treatment affects patients’ quality of life and their ability to perform daily activities. The research will also track how long it takes before patients need to start a different type of cancer treatment.

]]> Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer https://clinicaltrials.eu/trial/study-of-tarlatamab-with-durvalumab-carboplatin-and-etoposide-versus-standard-treatment-in-patients-with-previously-untreated-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:07:06 +0000 https://clinicaltrials.eu/trial/study-of-tarlatamab-with-durvalumab-carboplatin-and-etoposide-versus-standard-treatment-in-patients-with-previously-untreated-extensive-stage-small-cell-lung-cancer/ This clinical trial focuses on treating extensive stage small-cell lung cancer (ES-SCLC), an aggressive form of lung cancer that affects 10-15% of lung cancer patients and is commonly linked to smoking. The disease typically spreads quickly throughout the body, with about 70% of patients being diagnosed at an advanced stage when the cancer has already spread to other parts of the body.

The study will test a new treatment combination that includes tarlatamab, durvalumab, carboplatin, and etoposide, comparing it to a combination of durvalumab, carboplatin, and etoposide without tarlatamab. The purpose is to determine if adding tarlatamab to the standard treatment helps patients live longer. All medications will be given through an intravenous infusion, which means they are administered directly into a vein.

During the study, patients will be randomly assigned to receive either the new combination treatment or the standard treatment. The study will monitor how well patients respond to the treatment and track any side effects that may occur. The research team will continue to follow participants for several years to understand the long-term effects of the treatment.

]]> Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-and-standard-treatment-for-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:05:03 +0000 https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-and-standard-treatment-for-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study will compare the effects of a medication called Sacituzumab Govitecan, also known by its brand name Trodelvy, with the standard treatments currently used for this type of cancer. Sacituzumab Govitecan is a special kind of treatment called an Antibody-Drug Conjugate, which is designed to target and attack cancer cells more precisely.

The purpose of the study is to see how well Sacituzumab Govitecan works compared to the usual treatments in improving the condition of patients with ES-SCLC. Participants in the study will receive either Sacituzumab Govitecan or the standard treatment, which may include other medications. The study will monitor how the cancer responds to the treatment and how long patients live after receiving the treatment. Some participants may receive a placebo as part of the study.

The study will take place over a period of time, with regular check-ups and assessments to track the progress of the treatment. Participants will receive their treatment through an intravenous method, which means the medication will be given directly into a vein. The study aims to provide valuable information on the effectiveness of Sacituzumab Govitecan in treating ES-SCLC and to explore its potential as a new treatment option for patients with this type of lung cancer.

]]> Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-comparing-bms-986489-with-chemotherapy-to-atezolizumab-with-chemotherapy-for-first-line-treatment-in-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:03:04 +0000 https://clinicaltrials.eu/trial/study-comparing-bms-986489-with-chemotherapy-to-atezolizumab-with-chemotherapy-for-first-line-treatment-in-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The study aims to compare two different treatment combinations to see which one helps patients live longer. One group of participants will receive a combination of BMS-986489 (a fixed dose combination of BMS-986012 and nivolumab) along with chemotherapy drugs carboplatin and etoposide. The other group will receive atezolizumab with the same chemotherapy drugs.

The purpose of this study is to determine if the combination of BMS-986489 with chemotherapy is more effective than atezolizumab with chemotherapy in treating ES-SCLC. Participants will be randomly assigned to one of the two treatment groups. The study will monitor how long participants live after starting the treatment, as well as other factors like how long it takes for symptoms to worsen, the safety of the treatments, and how well the tumors respond to the treatments.

Throughout the study, participants will receive their treatments through an intravenous (IV) infusion, which means the medicine will be given directly into a vein. The study will continue until the estimated end date in 2031, with the goal of providing valuable information on the effectiveness and safety of these treatment combinations for people with ES-SCLC.

]]> Study of Ifinatamab Deruxtecan with Atezolizumab and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-ifinatamab-deruxtecan-with-atezolizumab-and-carboplatin-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:00:32 +0000 https://clinicaltrials.eu/trial/study-of-ifinatamab-deruxtecan-with-atezolizumab-and-carboplatin-for-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive-stage Small Cell Lung Cancer (ES-SCLC). The study is testing a new treatment called Ifinatamab deruxtecan, also known by its code name DS-7300a. This treatment is a special type of medicine called an antibody-drug conjugate, which is designed to target cancer cells more precisely. The study will also involve other medications, including Atezolizumab, a monoclonal antibody that helps the immune system fight cancer, and Carboplatin, a chemotherapy drug that kills cancer cells. Another drug, Etoposide, which is a topoisomerase inhibitor, may also be used in the study.

The purpose of this study is to assess the safety and tolerability of the combination of these treatments. Participants will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will be conducted in two parts. In the first part, participants will receive Ifinatamab deruxtecan along with Atezolizumab, with or without Carboplatin, as a first-line treatment. In the second part, the study will continue to monitor the effects of these treatments over time. The study aims to understand how well these treatments work together and how they affect the participants’ health.

Throughout the study, participants will have regular check-ups to monitor their health and any side effects they may experience. These check-ups will include various tests and assessments to ensure the safety of the participants and to gather information about how the treatments are working. The study is expected to continue until 2026, providing valuable insights into the potential benefits and risks of these treatments for people with Extensive-stage Small Cell Lung Cancer.

]]> Study of Atezolizumab, Carboplatin, and Etoposide with or Without Tiragolumab for Patients with Untreated Extensive-Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-atezolizumab-carboplatin-and-etoposide-with-or-without-tiragolumab-for-patients-with-untreated-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:59:12 +0000 https://clinicaltrials.eu/trial/study-of-atezolizumab-carboplatin-and-etoposide-with-or-without-tiragolumab-for-patients-with-untreated-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as extensive-stage small cell lung cancer (ES-SCLC). The study is investigating the effects of a combination of medications, including atezolizumab, carboplatin, and etoposide, with or without an additional medication called tiragolumab. Atezolizumab is a medication that helps the immune system fight cancer, while carboplatin and etoposide are chemotherapy drugs that work to stop cancer cells from growing. Tiragolumab is an experimental drug that is being tested to see if it can enhance the effects of atezolizumab.

The purpose of this study is to evaluate how well the combination of these drugs works in treating patients who have not yet received treatment for their ES-SCLC. Some participants will receive a placebo instead of tiragolumab to compare the outcomes. The study will monitor participants over a period of time to assess their progression-free survival, which means the length of time during and after treatment that a patient lives with the disease without it getting worse, and overall survival, which is the length of time from the start of treatment that patients are still alive.

Participants in the study will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will last for up to 72 weeks, during which time participants will have regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether adding tiragolumab to the treatment regimen can improve outcomes for patients with ES-SCLC.

]]> Study on Maintenance Therapy with Durvalumab and Olaparib for Patients with Extensive Disease Small-Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-durvalumab-and-olaparib-for-patients-with-extensive-disease-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:59:11 +0000 https://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-durvalumab-and-olaparib-for-patients-with-extensive-disease-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as small-cell lung cancer (SCLC), which is a fast-growing form of lung cancer. The study is specifically looking at patients with a subtype called extensive disease (ED) small-cell lung cancer, which means the cancer has spread widely in the body. The trial will use two medications: olaparib and durvalumab. Olaparib is taken as a tablet, while durvalumab, also known by its code name MEDI4736, is given as an infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of this study is to evaluate how effective these medications are when used as maintenance therapy, which means they are given after the initial standard treatment to help keep the cancer from coming back. The standard first-line treatment usually includes a combination of chemotherapy drugs like carboplatin or cisplatin, etoposide, and durvalumab. After completing this initial treatment, patients will receive olaparib and durvalumab to see if these medications can help maintain the benefits of the first treatment.

During the study, participants will receive the medications for a period of time, and their health will be monitored regularly. This includes checking for any side effects and assessing how well the cancer is being controlled. The study aims to understand if this combination of treatments can improve outcomes for patients with this type of lung cancer. Some participants may receive a placebo instead of the active medications to compare the effects. The trial is expected to continue until 2027, with recruitment starting in 2024.

]]> Study on Niraparib with Immunotherapy for Patients with SLFN11-Positive Extensive-Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-niraparib-with-immunotherapy-for-patients-with-slfn11-positive-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:56:55 +0000 https://clinicaltrials.eu/trial/study-on-niraparib-with-immunotherapy-for-patients-with-slfn11-positive-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as extensive-disease small cell lung cancer (ED-SCLC), which shows high levels of a protein called SLFN11. The study is testing the effects of adding a medication called niraparib to a treatment plan that includes a type of medicine known as an anti-PD-L1 antibody. These antibodies, such as atezolizumab and durvalumab, are used to help the immune system fight cancer. Niraparib is a tablet that works by blocking certain enzymes in cancer cells, which may help stop the cancer from growing.

The purpose of this study is to see how effective the combination of niraparib and anti-PD-L1 antibodies is in treating patients with this specific type of lung cancer. Patients who participate in the study will receive the treatment over a period of time, and their health will be monitored to see how the cancer responds. The study will also compare the effects of the treatment with a placebo to better understand its benefits.

Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein, and they will also take niraparib in tablet form. The study aims to provide more information on how well this combination works in preventing the cancer from getting worse and improving overall survival rates. The results will help determine if this treatment approach can be a beneficial option for patients with this type of lung cancer.

]]> Study of Pembrolizumab, Lenvatinib, and Chemotherapy for First-Line Treatment in Extensive-Stage Small Cell Lung Cancer Patients https://clinicaltrials.eu/trial/study-of-pembrolizumab-lenvatinib-and-chemotherapy-for-first-line-treatment-in-extensive-stage-small-cell-lung-cancer-patients/ Wed, 29 Apr 2026 14:47:37 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-lenvatinib-and-chemotherapy-for-first-line-treatment-in-extensive-stage-small-cell-lung-cancer-patients-2/ This clinical trial is focused on studying a type of lung cancer known as extensive-stage small cell lung cancer (ES-SCLC). The study will explore the effects of a combination treatment that includes the medications pembrolizumab and lenvatinib, along with chemotherapy drugs carboplatin and etoposide. Pembrolizumab is administered as a solution for infusion, while lenvatinib is taken in capsule form. The purpose of the study is to evaluate the safety and effectiveness of this combination treatment in patients who are receiving their first line of treatment for this type of lung cancer.

The study will be conducted in two parts. In the first part, the focus will be on assessing the safety and tolerability of lenvatinib when used with pembrolizumab and chemotherapy. This means checking how well patients can handle the treatment and identifying any side effects. In the second part, the study will look at how long patients can live without their cancer getting worse, which is known as progression-free survival. This will help determine if the combination treatment is effective in controlling the cancer.

Participants in the study will receive the treatment over a period of time, with regular monitoring by healthcare professionals. The study aims to provide valuable information on the potential benefits and risks of using pembrolizumab and lenvatinib together with chemotherapy for treating extensive-stage small cell lung cancer. This research could contribute to improving treatment options for patients with this type of cancer.

]]> Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-pembrolizumab-quavonlimab-and-lenvatinib-for-patients-with-advanced-small-cell-lung-cancer-needing-second-line-treatment/ Wed, 29 Apr 2026 14:30:40 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-pembrolizumab-quavonlimab-and-lenvatinib-for-patients-with-advanced-small-cell-lung-cancer-needing-second-line-treatment/ This clinical trial is focused on studying treatments for people with extensive-stage small cell lung cancer (ES-SCLC) who need a second-line therapy. The study involves the use of several investigational treatments, including Pembrolizumab, which is a type of medication known as an immune checkpoint inhibitor. Pembrolizumab is being tested in combination with other investigational agents such as Quavonlimab, Favezelimab, MK-4830, and Lenvatinib. These treatments are designed to help the immune system fight cancer cells more effectively.

The purpose of this study is to evaluate the safety and effectiveness of these treatment combinations. Participants will receive these medications either through an intravenous infusion, which means the medicine is given directly into a vein, or orally, in the form of capsules. The study will monitor participants for any side effects and measure how well the cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the investigational treatments.

Throughout the study, participants will have regular check-ups and assessments to track their health and the progress of their cancer. The study aims to provide valuable information on how these new treatment combinations can help people with ES-SCLC who have not responded to initial treatments. The trial is expected to continue until 2026, allowing researchers to gather comprehensive data on the long-term effects and benefits of these therapies.

]]> Study of BMS-986012 with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-bms-986012-with-chemotherapy-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:29:39 +0000 https://clinicaltrials.eu/trial/study-of-bms-986012-with-chemotherapy-for-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive-Stage Small Cell Lung Cancer (SCLC). The trial is testing a new treatment called BMS-986012, which is a special kind of medicine known as a human IgG1 monoclonal antibody. This medicine is designed to target a specific part of cancer cells. The study will also use standard chemotherapy drugs, cisplatin and etoposide, which are commonly used to treat this type of cancer.

The purpose of the study is to find out how safe and tolerable the new treatment is when used with chemotherapy, and to determine the best dose to use. The study will be conducted in several parts. Initially, participants will receive BMS-986012 along with four cycles of either cisplatin or another similar drug called carboplatin, combined with etoposide. After these cycles, participants will continue to receive BMS-986012 alone until the cancer progresses. In another part of the study, the effectiveness of the combination of BMS-986012 with chemotherapy will be compared to chemotherapy alone.

Participants in the study will be monitored for any side effects and how well the treatment works in controlling the cancer. The study aims to improve understanding of how this new treatment can be used to help people with extensive-stage SCLC. The trial will continue until the estimated end date in 2024, with the goal of providing valuable information on the potential benefits of BMS-986012 for patients with this type of lung cancer.

]]> Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer https://clinicaltrials.eu/trial/study-of-bms-986012-with-carboplatin-etoposide-and-nivolumab-for-first-line-treatment-in-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:28:46 +0000 https://clinicaltrials.eu/trial/study-of-bms-986012-with-carboplatin-etoposide-and-nivolumab-for-first-line-treatment-in-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial studies a combination treatment for Extensive-stage Small Cell Lung Cancer. The study tests a new treatment approach that combines several medications: BMS-986012 (an experimental antibody), carboplatin, etoposide, and nivolumab. The purpose is to evaluate how safe and effective this combination therapy is compared to standard treatment.

The study involves two different treatment approaches. One group of patients receives all four medications (BMS-986012, carboplatin, etoposide, and nivolumab) for the first part of treatment, followed by continued treatment with BMS-986012 and nivolumab. The other group receives only carboplatin, etoposide, and nivolumab initially, followed by nivolumab alone.

During the study, patients will undergo regular medical examinations and imaging tests such as computed tomography or magnetic resonance imaging to monitor how well the treatment is working. The researchers will track how the cancer responds to treatment and monitor any side effects that may occur. The study will also measure how long patients live without their cancer getting worse and their overall survival time.

]]> Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-lurbinectedin-and-atezolizumab-for-maintenance-therapy-in-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:27:47 +0000 https://clinicaltrials.eu/trial/study-of-lurbinectedin-and-atezolizumab-for-maintenance-therapy-in-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). The study is investigating the effects of two treatments: lurbinectedin and atezolizumab. Atezolizumab, also known by its code name RO5541267, is a medication that is already used in treating this type of cancer. Lurbinectedin, with the code name RO7508182, is being tested in combination with atezolizumab to see if it can improve outcomes for patients.

The purpose of the study is to compare the effectiveness of using lurbinectedin together with atezolizumab against using atezolizumab alone as a maintenance therapy. Maintenance therapy is a treatment given to help keep cancer from coming back after it has responded to initial treatment. Participants in the study will have already received a first round of treatment with atezolizumab, carboplatin, and etoposide, which are standard drugs used to treat ES-SCLC.

During the study, participants will be randomly assigned to receive either the combination of lurbinectedin and atezolizumab or atezolizumab alone. The study will monitor how long participants live without their cancer getting worse and their overall survival. The trial will also look at the safety of the treatments and any side effects that may occur. This study aims to provide more information on whether the combination of these drugs can offer better outcomes for patients with this type of lung cancer.

]]> Study of Ifinatamab Deruxtecan for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-ifinatamab-deruxtecan-for-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:27:23 +0000 https://clinicaltrials.eu/trial/study-of-ifinatamab-deruxtecan-for-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The treatment being tested is called Ifinatamab deruxtecan, which is also known by its code name DS-7300a. This treatment is a special kind of medicine called an Antibody Drug Conjugate (ADC), which is designed to target and attack cancer cells more precisely.

The purpose of the study is to evaluate how well Ifinatamab deruxtecan works in patients who have already received treatment for their lung cancer. Participants in the study will receive the treatment through an infusion, which means the medicine is given directly into the bloodstream through a vein. The study will follow participants over a period of time to observe the effects of the treatment on their cancer.

Throughout the study, participants will have regular visits to monitor their health and the progress of their cancer. These visits will include various tests and assessments to ensure the safety and effectiveness of the treatment. The study aims to provide valuable information on the potential benefits of Ifinatamab deruxtecan for patients with pretreated ES-SCLC.

]]> Study on Pembrolizumab and Olaparib for Patients with Extensive-Stage Small-Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-olaparib-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:27:16 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-olaparib-for-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). The study will explore the effectiveness of a treatment approach that combines chemotherapy and immunotherapy, followed by maintenance therapy using two medications: pembrolizumab and olaparib. Pembrolizumab is a type of immunotherapy that helps the immune system fight cancer, while olaparib is a medication that targets cancer cells with specific genetic features.

The purpose of the study is to evaluate how well this treatment approach works in preventing the cancer from getting worse. Participants will initially receive a combination of chemotherapy and immunotherapy. After this initial phase, they will continue with maintenance therapy using pembrolizumab and olaparib. The study will also include a comparison with a placebo to better understand the effectiveness of the treatment.

Throughout the study, participants will receive regular check-ups and monitoring to assess their health and the progress of the treatment. The study aims to provide valuable information on the potential benefits of this treatment approach for patients with ES-SCLC. The trial is expected to continue until 2026, with the goal of improving outcomes for individuals affected by this type of lung cancer.

]]> Study on the Effects of Defosbarasertib and Durvalumab for Patients with Extensive-Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-effects-of-defosbarasertib-and-durvalumab-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:27:16 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-defosbarasertib-and-durvalumab-for-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The study is exploring the potential benefits of adding a new treatment called Defosbarasertib (also known by its code name AZD2811) to the current standard maintenance therapy, which includes a medication called Durvalumab. Both medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective and safe the combination of AZD2811 and Durvalumab is when used as a maintenance therapy after initial treatment with platinum-based chemotherapy and Durvalumab. Participants in the study will receive these treatments and will be monitored over time to see how well they respond. The study will look at how many participants are alive and have not experienced cancer progression at different time points, such as 12 months after starting the maintenance therapy.

Throughout the study, participants will be regularly assessed to track their health and any changes in their condition. The study aims to gather information on the overall survival of participants, their progression-free survival, and any side effects they may experience. This information will help researchers understand the potential benefits and risks of using AZD2811 in combination with Durvalumab for treating ES-SCLC.

]]> Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings https://clinicaltrials.eu/trial/study-on-the-accuracy-of-owl-evo1-test-for-diagnosing-lung-cancer-in-patients-eligible-for-screening-or-with-suspicious-ct-findings/ Wed, 29 Apr 2026 14:26:14 +0000 https://clinicaltrials.eu/trial/study-on-the-accuracy-of-owl-evo1-test-for-diagnosing-lung-cancer-in-patients-eligible-for-screening-or-with-suspicious-ct-findings/ This clinical trial is focused on studying lung cancer and involves a new test called the OWL-EVO1 Breath Biopsy test. The test aims to help differentiate between individuals who may have lung cancer and those who do not. The study will use a special solution called D5-ethyl-beta-D-glucuronide, which is given through an infusion into the veins. This solution is a water-soluble substance that helps in the testing process.

The purpose of the study is to assess how accurately the OWL-EVO1 test can identify lung cancer in people who are undergoing screening or have findings on a CT scan that might suggest lung cancer. Participants will receive the test and be monitored to see how well it works in identifying lung cancer compared to other conditions that might look similar on a scan. The study will also look at the safety and tolerability of the test, ensuring that it is safe for participants to use.

Throughout the study, participants will receive the test and be observed over a period of time to gather information on its effectiveness and safety. The study will help determine if the OWL-EVO1 test can be a reliable tool for diagnosing lung cancer, potentially leading to earlier and more accurate detection of the disease.

]]> Study on the Effect of Adding Thoracic Radiotherapy to Durvalumab and Chemotherapy for Patients with Extensive Stage Small-Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-effect-of-adding-thoracic-radiotherapy-to-durvalumab-and-chemotherapy-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:25:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-adding-thoracic-radiotherapy-to-durvalumab-and-chemotherapy-for-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as extensive stage small-cell lung cancer. The trial is investigating whether adding a type of radiation treatment to a combination of medications can help patients live longer. The medications being used in this study include durvalumab, also known by its code name MEDI4736, which is a type of immunotherapy. Immunotherapy is a treatment that helps the body’s immune system fight cancer. This study also involves chemotherapy, which is a common cancer treatment that uses drugs to kill cancer cells.

The purpose of the study is to find out if combining radiation therapy with durvalumab and chemotherapy can improve the survival rate of patients with this type of lung cancer. Participants in the study will receive these treatments, and some may receive a placebo instead of the active medication. The study will monitor the participants over time to see how well the treatments work and to check for any side effects. The study aims to understand the benefits of this combined treatment approach over a period of several years.

Throughout the study, researchers will look at various outcomes, such as how long patients live after starting the treatment and how the cancer responds to the treatment. They will also assess the quality of life of the participants and any side effects they experience. This information will help determine if the addition of radiation therapy to the existing treatment plan can provide a significant benefit to patients with extensive stage small-cell lung cancer.

]]> Study on Durvalumab with Carboplatin or Cisplatin and Etoposide for First-Line Treatment in Patients with Extensive Stage Extrapulmonary Small Cell Carcinoma https://clinicaltrials.eu/trial/study-on-durvalumab-with-carboplatin-or-cisplatin-and-etoposide-for-first-line-treatment-in-patients-with-extensive-stage-extrapulmonary-small-cell-carcinoma/ Wed, 29 Apr 2026 14:25:52 +0000 https://clinicaltrials.eu/trial/study-on-durvalumab-with-carboplatin-or-cisplatin-and-etoposide-for-first-line-treatment-in-patients-with-extensive-stage-extrapulmonary-small-cell-carcinoma/ This clinical trial is focused on studying a type of cancer known as extensive stage extrapulmonary small cell carcinoma (EPSCC). This is a form of cancer that starts outside the lungs and spreads quickly. The study is testing a treatment that combines several medications to see how effective they are in treating this cancer. The medications being used in this study include Durvalumab, which is a type of drug called a monoclonal antibody that helps the immune system fight cancer, and chemotherapy drugs such as Carboplatin, Cisplatin, and Etoposide. These chemotherapy drugs work by stopping the growth of cancer cells.

The purpose of the study is to evaluate how well this combination of medications works in preventing the cancer from getting worse over a period of 12 months. Patients participating in the study will receive these medications through an infusion, which means the drugs are given directly into the bloodstream through a vein. The study will last for a maximum of 24 months, during which the patients will be monitored regularly to assess the treatment’s effects and any side effects that may occur.

Throughout the study, the health and progress of the patients will be closely observed to determine the safety and effectiveness of the treatment. The study aims to provide valuable information on whether this combination of medications can help improve the quality of life and survival rates for patients with this aggressive form of cancer. Participants will receive regular check-ups and assessments to ensure their well-being and to gather data on the treatment’s impact.

]]> Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-trilaciclib-and-topotecan-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:24:16 +0000 https://clinicaltrials.eu/trial/study-on-trilaciclib-and-topotecan-for-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is evaluating a treatment called Trilaciclib, which is given to patients before they receive a chemotherapy drug named Topotecan. The purpose of the study is to see if Trilaciclib can help patients live longer compared to those who receive a placebo before Topotecan. A placebo is a substance with no active medication, used for comparison in clinical trials.

Participants in the study will receive either Trilaciclib or a placebo before their Topotecan chemotherapy sessions. The study will monitor the overall survival of patients, which means the length of time patients live after starting the treatment. The trial will also look at other factors, such as how the cancer responds to the treatment and any side effects that may occur. The study is designed to last for a period of up to 120 days, during which patients will receive regular intravenous infusions of the study medications.

In addition to Trilaciclib and Topotecan, the study involves the use of other substances like Sodium Chloride and Glucose Monohydrate, which are commonly used in medical settings to support the administration of intravenous treatments. The trial aims to provide valuable information on the effectiveness and safety of using Trilaciclib in combination with Topotecan for treating patients with ES-SCLC.

]]> Study on the Effectiveness of Paclitaxel, Carboplatin, and Durvalumab for Patients with Extensive Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-paclitaxel-carboplatin-and-durvalumab-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:23:26 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-paclitaxel-carboplatin-and-durvalumab-for-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is investigating the effectiveness of a combination of treatments, including durvalumab (also known by its code name MEDI4736), paclitaxel, and carboplatin. These medications are given as an infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how well this combination of treatments works in patients with ES-SCLC. Participants in the study will receive these medications over a period of time, with durvalumab being administered for up to 48 weeks and the other medications for up to 12 weeks. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study will monitor participants’ health and response to the treatment, including their overall survival and any changes in their quality of life. The goal is to determine if this combination of treatments can improve outcomes for patients with this type of lung cancer. Participants will be closely observed for any side effects or adverse reactions to the medications throughout the study period.

]]> Study of Durvalumab, Cisplatin, Carboplatin, and Etoposide for Patients with Extensive Stage Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-durvalumab-cisplatin-carboplatin-and-etoposide-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:22:32 +0000 https://clinicaltrials.eu/trial/study-of-durvalumab-cisplatin-carboplatin-and-etoposide-for-patients-with-extensive-stage-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as extensive stage small cell lung cancer (SCLC). The trial will explore a treatment plan that combines several therapies to see if it can improve patient outcomes. The treatment involves using a combination of medications and therapies, including Durvalumab (also known by its code name MEDI4736), Cisplatin, Carboplatin, and Etoposide. These medications are given as solutions through an infusion, which means they are delivered directly into the bloodstream.

The purpose of the study is to test the feasibility and effectiveness of this treatment plan. The treatment will start with a combination of chemotherapy and radiotherapy, which is a type of cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. This will be followed by a more targeted form of radiotherapy called stereotactic radiotherapy, which aims to precisely target cancer cells while sparing healthy tissue. The study will also look at how well this treatment plan can help patients live longer without the cancer getting worse over a period of 12 months.

Participants in the study will receive the treatment over a period of time, with the initial phase involving chemotherapy and radiotherapy, followed by maintenance therapy with Durvalumab. The study aims to gather information on how well patients respond to this combination of treatments and whether it can improve their quality of life and survival rates. The trial is expected to continue until 2026, with recruitment starting in 2024.

]]>